Per‐ and Polyfluoroalkyl Substances and Knee Osteoarthritis: Data From the Osteoarthritis Initiative
Authors' conclusion
In a large cohort at risk for KOA, higher perfluorooctanoic acid and PFNA serum concentrations may be associated with a greater likelihood of symptomatic KOA incidence and knee pain progression.
Study context
- Population
- Case-cohort sample from the OA Initiative; 58% female, mean age 62 years, mean BMI 28.6 kg/m²case-cohort sample
- Participants
- 1,878 participants
- Exposure
- Higher vs lower serum concentrations of eight PFAS
- Outcome
- Incident symptomatic knee OA and clinically meaningful change in WOMAC knee pain score
- Follow-up
- 48 months
Methodological detailsweighted logistic regression, quantile g-computation (PFAS mixture)
- Weighted logistic regression
- Quantile g-computation (PFAS mixture)
Main finding
As reported in the abstract
Perfluorooctanoic acid (continuous), OR per IQR
1.12
95% CI 1.04–1.21
Perfluorononanoic acid (PFNA) third quartile, OR
1.63
95% CI 1.29–2.07
PFNA fourth quartile, OR
1.55
95% CI 1.19–2.01
Perfluorooctanoic acid serum 5.19–6.88 ng/mL (possible nonlinear relationship, greatest chance), OR
1.55
95% CI 1.21–1.97
Observational data: associations, not effects.
Further findings
Knee pain progression (clinically meaningful change in WOMAC knee pain) · 48 months
- Perfluorooctanoic acid (continuous), OR per IQR
- 1.10 (95% CI 1.03-1.18)
- PFNA (continuous), OR per IQR
- 1.06 (95% CI 1.01-1.11)
PFAS mixture (quantile g-computation), both outcomes
- Perfluorooctanoic acid and PFNA among the PFAS with the strongest positive weights for both outcomes
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →